Sun Pharma Advanced Research Co (NSE:SPARC) Institutional Ownership: 1.46% (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SPARC Sun Pharma Advanced Research Co Ltd NSE:SPARC
49 GF Score
Price ₹224.52
GF Value ₹83.82
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Sun Pharma Advanced Research Co Institutional Ownership?

Sun Pharma Advanced Research Co NSE:SPARC -1.31% 49 Institutional Ownership is 1.46% as of Jul. 22, 2026. GuruFocus rates NSE:SPARC with a GF Score™ of 49/100 and a GF Value™ of ₹83.82 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sun Pharma Advanced Research Co's institutional ownership is 1.46%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sun Pharma Advanced Research Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sun Pharma Advanced Research Co's Float Percentage Of Total Shares Outstanding is 0.00%.

Sun Pharma Advanced Research Co Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Sun Pharma Advanced Research Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sun Pharma Advanced Research Co Institutional Ownership Chart

Sun Pharma Advanced Research Co Historical Data

The historical data trend for Sun Pharma Advanced Research Co can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 2.31 2.32 2.33 2.15 2.23 2.22 2.28 2.03 1.49 1.46
NSE:SPARC
49GF Score
Sun Pharma Advanced Research Co Ltd NSE:SPARC
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sun Pharma Advanced Research Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 1.46% mean?
Sun Pharma Advanced Research Co (NSE:SPARC) has a Institutional Ownership of 1.46% as of Jul. 22, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Sun Pharma Advanced Research Co and its competitors.
Is Sun Pharma Advanced Research Co's Institutional Ownership too high?
Sun Pharma Advanced Research Co's current Institutional Ownership is 1.46%. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's Institutional Ownership compare to ZTS and UTHR?
Sun Pharma Advanced Research Co's Institutional Ownership of 1.46% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Sun Pharma Advanced Research Co and its competitors. Sun Pharma Advanced Research Co's current Institutional Ownership is 1.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (NSE:SPARC) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹83.82, compared to a current price of ₹224.52 — trading 167.9% above its estimated fair value. The current Institutional Ownership is 1.46%. Sun Pharma Advanced Research Co's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (NSE:SPARC), the current Institutional Ownership is 1.46% as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?

Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be overvalued. The current stock price of ₹224.52 is trading 167.9% above its estimated GF Value™ of ₹83.82. GuruFocus considers Sun Pharma Advanced Research Co to be Significantly Overvalued.

Key valuation signals for NSE:SPARC:

  • Institutional Ownership: 1.46%
  • GF Value™: ₹83.82 vs. price of ₹224.52 (167.9% above fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sun Pharma Advanced Research Co Business Description

Other Exchanges 532872:India
Address Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
49GF Score

Get the complete analysis for NSE:SPARC

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹224.52
Price
₹83.82
GF Value